Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program
- Institution
- EMOCHA MOBILE HEALTH, INC., MD
- Principal investigator
- Sebastian Seiguer
- Funding
- $650K
- Duration
- 2020–2026
Moonbase score
Still being scored
Abstract
Methadone is an effective treatment for opioid use disorder (OUD) yet historically the care delivery model requires directly-observed therapy (DOT) at opioid treatment programs which is a barrier to clients. Many factors ultimately led to the revision of regulations, paving the way for more flexible models of care. Our prior Phase I research demonstrated the feasibility, safety, and acceptability of an innovative mobile health platform to provide asynchronous, video DOT and to screen for symptoms of disease for patients treated for OUD with methadone; this proposal aims to test the implementation of video direct observe therapy (video-DOT) for methadone across a large, multisite OTP organization via a Hybrid Type 2 Effectiveness Implementation study with stepped wedge cluster randomized trial design.
Research team
- Kevin A. HallgrenPI
- Sebastian SeiguerPI
- Judith TsuiPI
LOADING MOONBASE SCORE
Questions for Emocha Mobile Health, Inc.
Emocha Mobile Health, Inc. hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.
Related grants
Same researchers, same topic, scored first.
- NIH · University of WashingtonNot yet scored
Training in Enhancing Structural Solutions in Addictions (TESSA) Program”
Geetanjali Chander · $356K · 2023–2028
- NIH · Emocha Mobile Health, Inc.Not yet scored
ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)
Susan Creary · $649K · 2023–2026
- NIH · Berkshire Biomedical CorporationNot yet scored
COPA: A clinical program to evaluate benefits of a hand-held, automated, personalized oral liquid dispensing system for take-home methadone medication management for patients with opioid use disorder.
John Timberlake · $326K · 2025–2026